IP Think Tank Global Week In Review

Author:Mr Duncan Bucknell
Profession:Duncan Bucknell

Here is IP Think Tank's weekly selection of top intellectual property news breaking in

the blogosphere and internet.

Highlights this week included:briefs filed in the US Supreme Court in an effort to revive

the doctrine of patent exhaustion and another positive step towards a single European patent

litigation system.

Please join the discussion by adding your comments on any of these stories, and please do

let me know if you think we've missed something important, or if there is a source you think

should be monitored.

You can separately subscribe to the IP Thinktank Global week in Review at http://duncanbucknell.com/subscribe/


Reputation and privacy in the online social media world: (IPWar's),

McAfee typosquatting study results and implications: (IPWar's),

Larry Lessig's comments on how creativity is being strangled by the law: (BLOG@IP::JUR)

Two interesting papers on Creative Commons: (CreativeCommons)

Friction and 'Warfighting': (IP Think Tank),

More on the controversy at WIPO over Kamil Idris' planned departure: (Intellectual

Property Watch), (IAM), (Patent Prospector),

Global IP Strategy and national differences: (IP Think Tank),

Report of the Standing Committee on the Law of Trademarks, Industrial Designs and

Geographical Indications (SCT): (WIPO),

IAM and Ocean Tomo to present the IP Business Congress 2008: (IAM),

Top 5 reasons not to settle IP litigation: (IP Think Tank),

USA, Europe and Japan patent offices have agreed on a single format for patent

applications to be accepted by all offices: (IPMenu),

Local vs international patent filers in the US, Europe & Japan: (Patently'O),


Settlements in pharma patent litigation in India (Generic Pharmaceuticals & IP),

Cosopt (orzolamide hydrochloride and timolol maleate) - Merck has Apotex's

non-infringement and invalidity counterclaims dismissed: (IPLaw360),

Fuzeon (Enfuvirtide) - Novartis sues Roche for patent infringement: (IPLaw360),

Teva's aggressive generic plans: (Generic Pharmaceuticals & IP),


New US litigation filings (Generic Pharmaceuticals & IP),

Glivec (imatinib) - Indian Patent Appeals Board Composition - Natco likely to appeal

decision not to include technical appeal board member: (Generic Pharmaceuticals & IP),

Glivec (imatinib) - Para IV Challenge in the US: (Generic Pharmaceuticals & IP),

Nexium (esomeprazole) - In Europe Astrazeneca has lost the substance patent, maintained

the manufacturing process patent [in amended form] and now has also maintained...

To continue reading